In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program

Journal of Immunology

Volumn 165, Issue 8, 2000, Pages 4731-4741

  Cochlovius, B ^a   Stassar, M ^a   Christ, O ^a   Raddrizzani, L ^a   Hammer, J ^a   Mytilineos, I ^a   Zoller, M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 39; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CASE REPORT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION;

EID: 0034667948     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.8.4731     Document Type: Article

References (87)

1. Tumor antigens discovery: Perspectives for cancer therapy
2. Tumor antigens recognized by T lymphocytes
3. Tumor immunology
4. Targeting gene therapy to cancer: A review
5. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes
6. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immunogene therapy
7. The majority of autolgous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pme117/gp100
8. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals
9. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro
10. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy
11. Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by primary in vitro immunization with peptide pulsed dendritic cells
12. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles
13. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: A study in an unselected group of HLA-A2.1-positive patients
14. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocytes epitope restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells
15. Immunogenicity of the ALLAVGATK (gp100(17-25))peptide in HLA-A3.1 melanoma patients
16. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides
17. Identification of a novel peptide derived from the melanoma-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line
18. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
19. Active immunization against cancer cells: Impediments and advances
20. Experimental vaccine strategies for cancer immunotherapy
21. Gene therapy for cancer: What have we done and where are we going?
22. Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity
23. Modulating the immune response to genetic immunization
24. DNA vaccination for cancer treatment
25. Plasmid DNA: A new era in vaccinology
26. DNA vaccination as cancer immunotherapy
27. New treatment options for patients with melanoma: Review of melanoma-derived T-cell epitope-based peptide vaccines
28. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro
29. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
30. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation
31. Vaccination with tumor-antigen-pulsed dendritic cells induced in vivo resistance to a B cell lymphoma
32. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms
33. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
34. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
35. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
36. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
37. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
38. Dendritic cells differentiated from human monocytes through a combination of IL-4, GM-CSF and IFN-γ exhibit phenotype and function of blood dendritic cells
39. Antigen processing for amateurs and professionals
40. Towards a genetic analysis of tumor rejection antigens
41. Genes encoding for tumor-specific rejection antigens
42. Peptides naturally presented by MHC class I molecules
43. MHC ligands and peptide motifs: First listing
44. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes
45. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
46. A fail-safe mechanism for maintaining self-tolerance
47. Two roles for CD4 cells in the control of the generation of cytotoxic T lymphocytes
48. The immune system
49. Immune response decisions at the single cell level
50. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
51. Cytotoxic T cell responses to DNA vaccination: Dependence on antigen presentation via class 11 MHC
52. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II-negative tumors
53. MHC class 11 transfected minor cells induce long-term tumor-specific immunity in autologous mice
54. Retrovirus-mediated gene transfer of B7-1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one
55. Human class 11 major histocompatibility complex gene transfer into murine neuroblastoma leads to loss of tumorigenicity, immunity against subsequent tumor challenge, and elimination of microscopic preestablished tumors
56. Recombinant gp100 protein presented by dendritic cells elicits a T helper cell response in vitro and in vivo
57. Tumor-specific MHC class II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells
58. HLA class II binding specificity and autoimmunity
59. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11
60. In silico generation of tissue-specific and promiscuous HLA ligand databases using chips and virtual HLA class 11 matrices
61. Identification of novel T cell epitopes in Lol p5a by computational prediction
62. Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice
63. Melanocyte lineage specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
64. Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines
65. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 3 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation
66. Alloreactive cytolytic T cell clones preferentially recognize conformational determinants on histocompatibility antigens: Analysis with genetically engineered hybrid antigens
67. Human melanoma therapy in the SC1D mouse: Targeting and activation of melanoma-specific cytotoxic T cells by bispecific antibody fragments is curative
68. Panning for lymphocytes: A method for cell selection
69. Improved engraftment of human tumours in SCID mice pretreated with radiation and anti-asialo GM1
70. Universally immunogenic T cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T cells
71. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells
72. Dendritic cells: From basic studies to therapeutic applications: Fourth international symposium on dendritic cells in fundamental and clinical immunology
73. Dendritic cells: Potential role in cancer therapy
74. Origin, maturation and antigen presenting function of dendritic cells
75. Dendritic cells presenting tumor antigen
76. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice
77. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
78. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
79. Cancer vaccines
80. + T cells in antitumor immunity
81. Autologous human monocyte derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α
82. + lymphocytes in the initiation of class 1-restricted reactivity to a tumor/self peptide
83. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes
84. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
85. Several common HLA-DR types share largely overlapping peptide binding repertoires
86. + T cells
87. + T cells in the antitumor immune response